What We're Reading: Page 2
Industry reads hand-picked by our editors
Jul 10, 2019
Jul 09, 2019
-
STAT
Sean Parker is nerding out on cancer research. And he’s doing it in style
-
Xconomy
After Amgen's Spark, Revolution Med Nabs $100M to Push RAS Cancer Drugs
-
Reuters
Novartis launches Adamis allergy shots in U.S. pharmacies amid EpiPen shortage
-
Healthcare Dive
Republican bid to dismantle ACA takes center stage
Jul 08, 2019
-
The New York Times
Trump Suggests Executive Order on Drug Prices, With a Scope That Is Unclear
-
The Wall Street Journal
Fast-Track Drug Approval, Designed for Emergencies, Is Now Routine
-
NPR
Tools That Help Doctors Figure Out Drug Prices Slow To Catch On
-
C&EN
How phenylketonuria, a once-neglected disease, became a proving ground for new drugs
Jul 03, 2019
-
MIT Technology Review
A third CRISPR baby may have already been born in China
-
The Wall Street Journal
Facebook, YouTube Overrun With Bogus Cancer-Treatment Claims
-
STAT
Real-world evidence trial generates real-world criticism, too
-
Reuters
States agree to pause lawsuits against bankrupt opioid maker Insys
Jul 02, 2019
Jul 01, 2019
-
Kaiser Health News
Have Cancer, Must Travel: Patients Left In Lurch After Hospital Closes
-
Bloomberg
Elizabeth Holmes Blames Journalist for Theranos Troubles
-
BioCentury
Why tissue-agnostic drug development needs NGS to go mainstream
-
The Wall Street Journal
At Purdue Pharma, Business Slumps as Opioid Lawsuits Mount
Previous
